Enhanced Diagnostic Portfolio
Quest Diagnostics has acquired the U.S. laboratory services business of Oxford Immunotec Global PLC, significantly expanding its portfolio of innovative infectious disease testing services. This acquisition incorporates Oxford Immunotec‘s renowned T-SPOT®.TB tuberculosis and Accutix™ tick-borne disease testing services into Quest Diagnostics’ comprehensive diagnostic offerings.
T-SPOT®.TB: A Cutting-Edge Tuberculosis Test
The T-SPOT®.TB test is an advanced interferon-gamma release assay (IGRA) designed to aid in the diagnosis of Mycobacterium tuberculosis infection and disease. This highly accurate test offers several advantages over traditional skin testing, including increased specificity, reduced cross-reactivity, and the ability to be performed with a single office visit.
Accutix™: Precise Tick-Borne Disease Detection
Quest Diagnostics now offers Accutix™, a comprehensive suite of tests for the detection of tick-borne diseases. These tests provide accurate and reliable results for Lyme disease, babesiosis, anaplasmosis, and ehrlichiosis, enabling timely diagnosis and appropriate treatment.
Strategic Collaboration and Supply Agreement
As part of the acquisition, Oxford Immunotec will continue to manufacture and supply T-SPOT®.TB test kits and related accessories to Quest Diagnostics under a long-term supply agreement. Additionally, the two companies have entered into a strategic collaboration agreement to promote the continued growth of T-SPOT®.TB testing in the United States.
Commitment to Physician Choice
Quest Diagnostics remains committed to providing physicians with a comprehensive range of testing options. The company will continue to offer QuantiFERON TB testing services, ensuring that healthcare providers have access to multiple blood-based TB testing methods.
About Quest Diagnostics
Quest Diagnostics is a leading provider of diagnostic information services, empowering individuals to take proactive steps towards improved health outcomes. With the world’s largest clinical laboratory database, Quest Diagnostics leverages its expertise to identify and treat diseases, promote healthy behaviors, and enhance healthcare management. Serving one in three adult Americans and half the physicians and hospitals in the United States, Quest Diagnostics is committed to delivering actionable insights that transform lives.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global diagnostics company dedicated to developing and commercializing innovative tests for immune-regulated conditions. The company’s flagship product, T-SPOT®.TB, has received regulatory approvals in over 50 countries and is widely recognized for its accuracy and convenience in diagnosing tuberculosis infection.
